drugset / Trial / NCT05785065
Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
Phase 2
Recruiting
35 enrolled
University of Montreal Hospital Centre (CHUM)
Canadian Institutes of Health Research (CIHR) · collabInstitut universitaire de cardiologie et de pneumologie de Québec, University Laval · collabJewish General Hospital · collabMcGill University · collabSclérodermie Québec · collabUniversity of Calgary · collab
RandomizedParallel-groupQuadruple-blindOther
Summary
The goal of this pilot study is to assess the feasibility of a larger study on the efficacy of mycophenolate mofetil in people diagnosed with systemic sclerosis with mild lung involvement. Participants will be recruited over 12 months at 3 academic centers and assigned randomly to receive either mycophenolate mofetil or placebo, a look-alike substance that contains no active drug, for 96 weeks.
Timeline
- Start
- 2024-08-29
- Primary completion
- 2026-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mycophenolate Mofetil | Small molecule | 1000 mg | Oral |